Terconazole is an antifungal drug used in the treatment of vulvovaginal candidiasis. It is classified as a triazole ketal derivative.
- Mechanism
- Curator reviewed
Terconazole may exert its antifungal activity by disrupting normal fungal cell membrane permeability. Terconazole and other triazole antifungal agents inhibit cytochrome P450 14-alpha-demethylase in susceptible fungi, which leads to the accumulation of lanosterol and other methylated sterols and a decrease in ergosterol concentration. Depletion of ergosterol in the membrane disrupts the structure and function of the fungal cell leading to a decrease or inhibition of fungal growth.
- Primary indication
- For the treatment of candidiasis (a yeast-like fungal infection) of the vulva and vagina.Curator reviewed · 1 structured indication
- Formula / weight
- C26H31Cl2N5O3 · 532.47 g/mol (avg)
- First approval
- Canada, 1999 · United States, 1987
- Brand names
Resolves to
BLSQLHNBWJLIBQ-ZEQKJWHPSA-NSMILESCC(C)N1CCN(CC1)C1=CC=C(OC[C@@H]2CO[C@](CN3C=NC=N3)(O2)C2=C(Cl)C=C(Cl)C=C2)C=C1What you can answer from here — as of September 13, 2026
Which drugs share a target with Terconazole, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account